Please assess the completion status of the following clinical trial:

Trial Title: Minocycline in the Treatment of Angelman Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The participant is between the ages of 4 to 12 years old.~2. The participant has been previously diagnosed with AS by clinical evaluation.~3. The participant's diagnosis has molecular confirmation (e.g. karyotyping, fluorescent in situ hybridization (FISH), DNA methylation test or sequencing of the ubiquitin-protein ligase E3A gene) of the diagnosis.~4. The participant has a CGI-Severity Score of at least 4 indicating a moderate level of behavioral difficulty.~5. The participant is male or female.~6. The participant has an acceptable surrogate capable of giving consent on the participant's behalf.~Exclusion Criteria:~1. The participant was diagnosed with AS with no identifiable molecular abnormality.~2. The participant has a known allergy to MC or tetracycline.~3. The participant is currently enrolled in a study in which a drug, vitamin or dietary manipulation is used in the treatment of AS.~4. The participant suffers from severe or uncontrolled seizures or any other medical condition rendering the patient unstable.~5. The participant suffers from cardiovascular, respiratory, liver, kidney or hematologic disease.~6. The participant suffers from liver disease or elevated liver function tests.~7. The participant has a history of neutropenia, anemia or thrombocytopenia.~8. The participant has a history of systemic lupus erythematosus or an anti-nuclear antibody (ANA) titer or \>1:40.~9. The participant is pregnant or at risk of becoming pregnant (sexually active females).~10. The participant experiences persistent psychotic symptoms.~11. The participant (or a parent/caregiver) is not willing to participate in clinic visits.~12. The participant experiences severe symptoms judged to likely to endanger the participant's safety or the safety of others.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Children with Angelman Syndrome (Type: EXPERIMENTAL): Children with a molecularly confirmed diagnosis of Angelman Syndrome meeting the protocol requirements will be selected randomly. All participants will receive the study drug, minocycline, over an identical time course. Participants will undergo identical baseline, 8 and 16 week follow up assessments.

Based on this trial design, predict the completion outcome and termination type (if applicable).